

Introducing **Acetium®**

Patented, novel solution for:

- Atrophic gastritis
- Migraine
- Asian flush
- Smoking cessation



Acetium® Product Family

- Patented, unique products to eliminate carcinogenic acetaldehyde
- Provides solutions for the aforementioned health risks
- New market field, no actual competitors
- Wealth of scientific data available

Acetium Capsules

- Effectively eliminates acetaldehyde in an acid-free stomach (induced by *Helicobacter pylori* infection and / or PPI usage)
- Pending clinical trials:
 - Treatment of atrophic gastritis (improved gastric acid secretion)
 - Prevention of migraine type headache (migraine or cluster/Horton headache)
 - Prevention of Asian flush syndrome (prevention of alcohol-induced flushing and hypersensitivity reactions)



Acetium Lozenge

- Effectively removes acetaldehyde* from saliva during smoking
- Pending clinical trial:
 - Reduction of nicotine dependence and help with smoking cessation and/or reduction



*Acetaldehyde in tobacco smoke significantly increases the risk of oral and other upper digestive system cancers

Acetium Commercialisation

- Biohit has already launched Acetium products in Finland and Canada
- 80 % of the pharmacies in Finland stocked Acetium within 4 months after launch and solid increase of sales continues
- Licensing or distribution partners in China, Canada, Mexico and several other countries
- Dynamic product support and scientific database
- Clear, simple messages for each target group
- Sales material packages and templates readily available



Summary and our suggestion

- Acetium capsules bind carcinogenic acetaldehyde locally in the stomach and Acetium lozenges from saliva during smoking.
- Many new indications under clinical trials.
- We offer unique in-licensing or distribution opportunities for Acetium products - patented, CE marked and registered trademarks of Biohit.

EXCEPTIONAL OPPORTUNITY WITH A NOVEL PRODUCT FOR A NEW INDICATION!

Acetaldehyde is a carcinogen

In October 2009 WHO/IARC classified acetaldehyde as a Group I human carcinogen*

- Same group as, radium, benzene, asbestos and, tobacco smoke.
- From 1996 genetic, epidemiological and biochemical studies have indisputably proven that acetaldehyde acts as a local carcinogen in the upper digestive tract

*Acetaldehyde associated with consumption of alcoholic beverages is classified as Group 1 carcinogen to humans (October 2009 WHO/IARC).

Scientific references:

Linderborg K, et al. Reducing carcinogenic acetaldehyde exposure in the achlorhydric stomach with cysteine. Alcohol Clin Exp Res 2011; 35(3):516-522.

Salaspuro M. Interactions of alcohol and tobacco in gastrointestinal cancer. J Gast Hepatol 2012; 27 (Suppl.2):135-139.

Salaspuro M. Acetaldehyde and gastric cancer. J Dig Dis. 2011 Apr;12(2):51-9.

Salaspuro M. Acetaldehyde as a common denominator and cumulative carcinogen in digestive tract cancers. Scand J Gastroenterol 2009; 44(8):912-25.

Salaspuro M. Acetaldehyde, microbes, and cancer of the digestive tract. Review. Crit Rev Clin Lab Sci 2003; 40(2):183-208.

Salaspuro V, et al. Removal of acetaldehyde from saliva by a slow-release buccal tablet of L-cysteine. Int J Cancer 2002; 97:361-364.

Salaspuro V, et al. (2006) Eliminating carcinogenic acetaldehyde by cysteine from saliva during smoking. Cancer Epidemiol Biomarkers Prev 2006; 15:146-149.

Väkeväinen S, et al. Hypochlorhydria induced by a proton pump inhibitor leads to intragastric microbial production of acetaldehyde from ethanol. Aliment Pharmacol Ther 2000;14:1511-1518.

Yokoyama A, et al. Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. Carcinogenesis 1998; 19:1383-1387.

Yokoyama A, et al. Helicobacter pylori, chronic atrophic gastritis, inactive aldehyde dehydrogenase-2, macrocytosis and multiple upper aerodigestive tract cancers and the risk for gastric cancer in alcoholic Japanese men. J Gastroenterol Hepatol 2007; 22:210-217.

